Expressions and clinical significance of Cyr61 and β-catenin in gallbladder carcinoma

Objective: To evaluate the expressions of Cyr61 and β-catenin protein in gallbladder carcinoma tissues and investigate their association with the clinicopathologic features of gallbladder carcinoma patients. Methods: The expressions of Cyr61 and β-catenin protein in 50 cases of gallbladder carcinoma and 19 cases of normal tissue were detected by immunohistochemical S-P method. Results: (1) The positive expression rate of Cyr61 in gallbladder carcinoma tissues was 66.0% (33/50), which was significantly higher than that in the normal tissues group (26.3%). The expression of Cyr61 was related to tumor differentiation, TNM stage and lymph node metastasis of gallbladder carcinoma (P=0.010, P=0.014, P=0.007; P<0.05). (2) The positive expression rate of β-catenin in gallbladder carcinoma tissues was 84.0% (42/50), which was significantly higher than that in the normal tissues group 15.7% (3/19); the expression of β-catenin was related to tumor differentiation, TNM stage and lymph node metastasis of gallbladder carcinoma (P=0.018, P=0.002, P=0.024; P<0.05). (3) Correlation test showed that Cyr61 and β-catenin were positively correlated in gallbladder carcinoma and adjacent normal tissues (r=0.378, P<0.05). Conclusion: Cyr61 and β-catenin are highly expressed in gallbladder carcinoma tissues. Cyr61 and β-catenin expressions are closely related to the clinicopathologic features (tumor differentiation, TNM staging and lymph node metastasis) in gallbladder carcinoma. Cyr61 and β-catenin may have a synergistic effect in promoting progression and development of gallbladder carcinoma. Combined detection of Cyr61 and β-catenin in gallbladder carcinoma tissues will contribute to the clinical diagnosis and prognosis.